Billions of dollars now flow into the longevity industry, yet no one can say for sure that aging can be slowed in humans. A recent review lumps many anti-aging approaches together, and a well-known longevity commentator argues that this hides the fact that some bets are far stronger than others.
The cautious camp and the builders
Reason opens with a sharp observation: academia and Big Pharma often share the same instinct, which is to wait until something is proven beyond doubt, either to work or to make money. From that vantage point, the longevity field is an experiment still running, with its outcome undecided. Can aging be slowed or reversed in humans the way it can in lab animals?
Plenty of scientists, entrepreneurs and patient advocates refuse to wait. Without them there would be no longevity industry. Reason’s view is that many of the lines of research look promising, and the real question is how much extra life they can deliver. Victories, he adds, are not won by staying on the sidelines.
What the review actually says
The review itself is a cautious survey. Aging is the strongest risk factor for heart disease, cancer, diabetes and neurodegeneration, so drugs that act on the core biological pathways of aging might extend healthspan, the years lived in good health. The authors focus on human evidence and on one distinction in particular: improving a lab marker is not the same as improving how long or how well people actually live.
By that standard, metformin (a diabetes drug) and rapamycin (an immune-modulating drug) have the deepest evidence, but proof of broad anti-aging benefit in people is still thin. Statins, SGLT2 inhibitors, GLP-1 drugs and menopausal hormone therapy clearly help with specific conditions, but whether they slow aging itself is unproven. The authors call the field promising but incompletely validated. Missing pieces include agreed-upon biomarkers of biological aging, knowing who responds best, optimal timing, and long-term safety.
Reason’s objection: not all approaches are equal
Reason’s main complaint is that the review groups very different therapies together. In his assessment, boosting NAD+, a molecule involved in cellular energy and repair, has unreliable animal data, a small effect size and a long record of disappointing human trials. Senolytics, which clear out old “zombie” cells that have stopped dividing but keep releasing inflammatory signals, have extensive and consistent animal data and large effects on age-related conditions. Their human data is still mixed and comes from only a few early trials.
The two approaches also reflect different philosophies. NAD+ boosting tries to keep an aging cell running better, while senolytics aim to remove damaged cells that harm their neighbors.
Why this matters for ordinary people
For anyone tempted by anti-aging supplements or clinics, the lesson is that “longevity” is not one thing. A therapy backed by strong animal data and a clear mechanism is a different proposition from one that raises a blood marker but has repeatedly failed to change human health. Even the stronger candidates have not been proven in people.
What comes next
The review’s authors call for large, well-powered randomized trials that combine standardized measures of biological aging with outcomes that matter, such as disease and function. They also want smarter patient selection, better timing and careful long-term safety monitoring. That is how the debate between cautious and bold will eventually be settled: with human results.
Source: This article draws on a post titled “A Conservative View of the Geroscience Endeavor” by the author Reason on the Fight Aging! blog (September 30, 2026), which comments on the open-access review “Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.”
https://www.fightaging.org/archives/2026/09/a-conservative-view-of-the-geroscience-endeavor
Transparency Note: This article was prepared with the assistance of artificial intelligence technologies. Every piece is thoroughly reviewed and verified by our editorial team, who retain full responsibility for the final content.
Picture: Gemini AI